Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 4;44(4):784-791.
doi: 10.5937/jomb0-54911.

Predictive levels of vascular endothelial growth factor (VEGF), thymidine kinase 1 (TK1) with interleukin-6 (IL-6), plasma T cells, NK cells as well as B cells in treating diffuse large B-cell lymphoma receiving rituximab

Lihua Tian  1 , Baoan Luo  1 , Jun Tang  1 , Jiagui Ye  2
Affiliations

Predictive levels of vascular endothelial growth factor (VEGF), thymidine kinase 1 (TK1) with interleukin-6 (IL-6), plasma T cells, NK cells as well as B cells in treating diffuse large B-cell lymphoma receiving rituximab

Lihua Tian et al. J Med Biochem. .

Abstract
in English, Serbian

Background: The aim was to explore the effect of rituximab in combination with chemotherapy in treating diffuse large B-cell lymphoma and levels of vascular endothelial growth factor (VEGF), thymidine kinase 1(TK1) with interleukin-6 (IL-6), plasma T cells, NK cells as well as B cells.

Methods: Eighty patients admitted to Lujiang County People's Hospital from January 2022 to January 2024 were included. The control group accepted cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy regimens. The research group was treated with rituximab based on the control group. The clinical effects, vascular endothelial growth factor (VEGF), thymidine kinase 1 (TK1) and interleukin-6 (IL-6) levels, lymphocyte subsets index, quality of life and occurrence of adverse reactions were compared in both groups.

Results: The research group's total clinical effective rate was better than the control group's (P<0.05). After therapy, compared to the control group, vascular endothelial growth factor, thymidine kinase 1, and interleukin-6 levels in the research group presented lower (P<0.05), plasma T cells, natural killer cells along with B cells in the research group presented lower (P<0.05), and Quality of Life Core Questionnaire-Core 30 scores in the research group presented higher (P<0.05). There was no difference in adverse reactions between the two groups (P>0.05).

Conclusions: Rituximab combined with chemotherapy is effective in treating DLBCL patients, which can reduce serum-related factors promoting immune function and quality of life. Our study may provide compelling evidence for supporting the therapeutic regimen of rituximab combined with chemotherapy in DLBCL patients.

Uvod: Cilj je bio da se ispita efekat rituksimaba u kombinaciji sa hemoterapijom u lečenju difuznog velikog B-ćelijskog limfoma, kao i nivoa vaskularnog endotelnog faktora rasta (VEGF), timidinske kinaze 1 (TK1) sa inter leukinom-6 (IL-6), plazma T ćelijama, NK ćelijama i B ćelijama.

Metode: U istraživanje je bilo uključeno 80 pacijenata primljenih u Narodnu bolnicu okruga Lujiang od januara 2022. do januara 2024. Kontrolna grupa je primala hemoterapijski režim koji je uključivao ciklofosfamid, dokso-rubicin, vinkristin i prednizon. Grupa ispitanika je, pored terapije kontrolne grupe, bila lečena i rituksimabom. Upoređivani su klinički efekti, nivoi vaskularnog endotelnog faktora rasta (VEGF), timidinske kinaze 1 (TK1) i interleukina-6 (IL-6), indeks podgrupa limfocita, kvalitet života i učestalost neželjenih reakcija kod obe grupe.

Rezultati: Ukupna klinička efikasnost u grupi ispitanika je bila bolja nego u kontrolnoj grupi (P<0,05). Nakon terapije, u poređenju sa kontrolnom grupom, nivoi vaskularnog endotelnog faktora rasta, timidinske kinaze 1 i interleukina-6 u grupi ispitanika su bili niži (P<0,05). Nivoi plazma T ćelija, prirodnih ćelija ubica (NK ćelija) i B ćelija su takođe bili niži u grupi ispitanika (P<0,05). Rezultati upitnika o kvalitetu života (Core 30) su u grupi ispitanika bili viši (P<0,05). Nije bilo razlike u učestalosti neželjenih reakcija između dve grupe (P>0,05).

Zaključak: Rituksimab u kombinaciji sa hemoterapijom je efika san u lečenju pacijenata sa DLBCL, jer može da smanji se rumske faktore povezane sa imunitetom, da poboljša funkciju imunog sistema i kvalitet života. Naša studija može da pruži ubedljive dokaze koji govore u prilog terapijskog režima rituksimaba u kombinaciji sa hemoterapijom kod pacijenata sa DLBCL.

Keywords: chemotherapy; diffuse large B-cell lymphoma; lymphocyte subsets index; rituximab.

PubMed Disclaimer

Conflict of interest statement

All the authors declare that they have no conflict of interest in this work.Conflict of Interest: The authors stated that they have no conflicts of interest regarding the publication of this article.

Figures

Figure 1
Figure 1. Diagnostic value of miR-124-3p, miR-944 and combined diagnosis.
Figure 2
Figure 2. Lymphocyte subsets index in both groups. #P<0.05, in contrast to before therapy. *P<0.05, in contrast to CG.
Figure 3
Figure 3. Quality of life in both groups. #P<0.05, in contrast to before therapy. *P<0.05, in contrast to CG.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Li S, Young K H, Medeiros L J. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74. - PubMed
    1. Li X, Mohammadi M R. Combined Diagnostic Efficacy of Red Blood Cell Distribution Width (RDW), Prealbumin (PA), Platelet-to-Lymphocyte Ratio (PLR), and Carcino-embryonic Antigen (CEA) as Biomarkers in the Diagnosis of Colorectal Cancer Cell Mol Biomed Rep. 2023;3(2):98. doi: 10.55705/cmbr.2023.374804.1088. - DOI
    1. Barraclough A, Hawkes E, Sehn L H, Smith S M. Diffuse large B-cell lymphoma. Hematological Oncology. 2024;42(6):e3202. doi: 10.1002/hon.3202. - DOI - PMC - PubMed
    1. Lee S F, Vellayappan B A, Wong L C, Chiang C L, Chan S K, Wan E Y, et al Cardiovascular diseases among diffuse large B-cell lymphoma long-term survivors in Asia: A multistate model study. ESMO Open. 2022;7(1):100363. doi: 10.1016/j.esmoop.2021.100363. - DOI - PMC - PubMed
    1. Alduaij W, Collinge B, Ben-Neriah S, Jiang A, Hilton L K, Boyle M, et al Molecular Determinants of Clinical Outcomes In a Real-World Diffuse Large B-cell Lymphoma Population. Blood. 2023;141(20):2493. doi: 10.1182/blood.2022018248. - DOI - PubMed

LinkOut - more resources